A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis

ClinicalTrials.gov ID: NCT02465606

Public ClinicalTrials.gov record NCT02465606. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Persistent, Moderate to Severe Atopic Dermatitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective for this study is to evaluate the safety of lebrikizumab compared with Topical Corticosteroids (TCS) alone in patients with persistent moderate to severe Atopic Dermatitis (AD) that is inadequately controlled with TCS.

Study identification

NCT ID: NCT02465606
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Hoffmann-La Roche; Industry
Enrollment: 55 participants

Conditions and interventions

Conditions

Atopic Dermatitis

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 30, 2015 (Actual)
Primary completion: May 30, 2016 (Actual)
Completion: May 30, 2016 (Actual)
Last update posted: Jan 27, 2020

2015 – 2016

United States locations

U.S. sites: 12
U.S. states: 9
U.S. cities: 12

Facility	City	State	ZIP	Site status
T. Joseph Raoof Md, Inc.	Encino	California	91436	—
Allergy and Asthma Relief Experts	Granada Hills	California	91344	—
Allergy and Asthma Associates of Southern California - CRN	Mission Viejo	California	92691	—
Forward Clinical Trials	Tampa	Florida	33624	—
Dermatology Specialists Research, LLC	Louisville	Kentucky	40241	—
Respiratory Medicine Research; Institue of Michigan P.L.C.	Ypsilanti	Michigan	48197	—
Sadick Research Group	New York	New York	10075	—
Montefiore Medical Center	The Bronx	New York	10467	—
Oregon Medical Research Center	Portland	Oregon	97223	—
Temple University Hospital	Philadelphia	Pennsylvania	19140	—
Asthma & Allergy Physicians of Rhode Island Clinical Research Institute (AAPRI CRI)	Warwick	Rhode Island	02865	—
Center for Clinical Studies	Cypress	Texas	77433	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02465606, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 27, 2020 · Synced Oct 20, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02465606 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →